실적분석 2026년 8월 10일

Alamar Biosciences ($ALMR) Q2 2026 Earnings Analysis — Revenue Beats Estimates and New Annual Guidance Issued

Earnings Scorecard

Revenue: $29.4M (+82% YoY, vs. estimate $25.94M) ✅ Beat

EPS: GAAP loss per share of $(0.22) (estimate was non-GAAP $(0.32) — different basis, not directly comparable)

Guidance: Newly issued — FY2026 revenue of $116M–$120M (midpoint implies +59% YoY growth)

Stock reaction: After-hours +0.00% ($27.99) — as of 05:15 KST on 08-11

The Positives

Revenue beat: Q2 revenue of $29.4M, up 82% YoY, exceeding consensus

Consumables surge: Consumables revenue of $15.5M, a 147% jump YoY

Gross margin expansion: Gross margin rose to 60% from 53% a year earlier

New instrument placements and demand for multi-analyte panels combined to shift the revenue mix toward higher-margin consumables. Launches of new content such as the plasma tau assay and immunology panels, along with expanded collaborations around large-scale sample data, further reinforced the growth drivers.

The Negatives

Net loss widens: Q2 net loss of $13.2M vs. $7.0M a year earlier

Operating expenses surge: Operating expenses of $31.2M, up 89% YoY

Losses persist: Operating loss of $13.5M — profitability not yet in sight

Investment in headcount, R&D, and infrastructure, combined with public-company costs, drove the increase in expenses. Given the company is in an investment-for-growth phase, the pace of revenue growth and platform adoption matters more in the near term than a narrower loss.

What Management Said

The CEO pointed to the strong consumables growth and the expansion of the panel portfolio into new disease areas as evidence that the company is positioned to extend its growth momentum into upcoming quarters. The market will likely focus on whether the newly introduced annual revenue outlook is backed by actual adoption in the second half and sustained consumables demand.

Market Reaction and Key Things to Watch

Although revenue topped estimates and new annual guidance was issued, much of the growth optimism appears to have already been priced in, and the wider loss was also confirmed — leaving the market in a wait-and-see stance, it seems.

Confirm whether consumables revenue growth can stay elevated through the second half.

Track progress toward the midpoint of the annual revenue guide alongside the trajectory of new instrument placements.

Check whether gross margin expansion continues despite the rise in operating expenses.